
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
1 Department of Neurological Surgery; 2 Experimental Therapeutics Program, Division of Medical Oncology, Department of Medicine; and 3 Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University Medical Center, New York, New York
Requests for reprints: Robert L. Fine, Experimental Therapeutics Program, Division of Medical Oncology, Department of Medicine, Columbia University Medical Center, 650 West 168th Street, BB 20-05, New York, NY 10032. Phone: 212-305-1168; Fax: 212-305-7348. E-mail: rlf20{at}columbia.edu
We have shown that a COOH-terminal peptide of p53 (amino acids 361382, p53p), linked to the truncated homeobox domain of Antennapedia (Ant) as a carrier for transduction, induced rapid apoptosis in human premalignant and malignant cell lines. Here, we report that human and rat glioma lines containing endogenous mutant p53 or wild-type (WT) p53 were induced into apoptosis by exposure to this peptide called p53p-Ant. The peptide was comparatively nontoxic to proliferating nonmalignant human and rat glial cell lines containing WT p53 and proliferating normal human peripheral marrow blood stem cells. Degree of sensitivity to the peptide correlated directly with the level of endogenous p53 expression and mutant p53 conformation. Apoptosis induction by p53p-Ant was quantitated by terminal deoxynucleotidyl transferasemediated dUTP nick end labeling assay and Annexin V staining in human glioma cells in vitro and in a syngeneic orthotopic 9L glioma rat model using convection-enhanced delivery in vivo. The mechanism of cell death by this peptide was solely through the Fas extrinsic apoptotic pathway. p53p-Ant induced a 3-fold increase in extracellular membrane Fas expression in glioma cells but no significant increase in nonmalignant glial cells. These data suggest that p53 function for inducing Fas-mediated apoptosis in gliomas, which express sufficient quantities of endogenous mutant or WT p53, may be restored or activated, respectively, by a cell-permeable peptide derived from the p53 COOH-terminal regulatory domain (p53p-Ant). p53p-Ant may serve as a prototypic model for the development of new anticancer agents with unique selectivity for glioma cancer cells and it can be successfully delivered in vivo into a brain tumor by a convection-enhanced delivery system, which circumvents the blood-brain barrier. [Mol Cancer Ther 2006;5(1):208]
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Note: P.B. Senatus and Y. Li contributed equally to the work. J.N. Bruce and R.L. Fine are senior authors.
4 Y. Li and R.L. Fine, unpublished data
5 J.N. Bruce and R.L. Fine, unpublished data.
Received 6/ 7/05; revised 9/19/05; accepted 10/14/05.
This article has been cited by other articles:
![]() |
E. Guida, A. Bisso, C. Fenollar-Ferrer, M. Napoli, C. Anselmi, J. E. Girardini, P. Carloni, and G. Del Sal Peptide Aptamers Targeting Mutant p53 Induce Apoptosis in Tumor Cells Cancer Res., August 15, 2008; 68(16): 6550 - 6558. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |